tm logo

Monitor this mark

View On USPTO

OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Live/Registered
REGISTERED

on 08 Aug 2023

Last Applicant/ Owned by

Bristol-Myers Squibb Company

Route 206 & Province Line Road

Princeton

NJ

08543

Serial Number

97342302 filed on 01st Apr 2022

Registration Number

7130293 registered on 08th Aug 2023

in the Principal Register

Correspondent Address

Marilyn F. Kelly

Marilyn F. Kelly

P.O. BOX 4000

TRADEMARK DEPT., MAILSTOP D.4243

PRINCETON,NJ 08648-4000

Filing Basis

1. filed as use application

2. use application currently

Disclaimer

NO DATA

OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)

Pharmaceutical preparations for human use comprising monoclonal antibodies for the treatment and prevention of cancer

Classification Information

Class [005]
Pharmaceutical Products

Pharmaceutical preparations for human use comprising monoclonal antibodies for the treatment and prevention of cancer

First Use Date in General

22nd Mar 2022

First Use Date in Commerce

22nd Mar 2022

Mark Details

Serial Number

No 97342302

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 00161293-US

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

26.17.09 -

Curved line(s), band(s) or bar(s)

Legal History

Show more

Status DateAction Taken
08th Aug 2023REGISTERED-PRINCIPAL REGISTER
08th Aug 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
02th Aug 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
02th Aug 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02th Aug 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
23rd May 2023PUBLISHED FOR OPPOSITION
23rd May 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03rd May 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17th Apr 2023EXAMINERS AMENDMENT -WRITTEN
17th Apr 2023EXAMINERS AMENDMENT E-MAILED